RU2017106794A - Биомаркеры для прогнозирования ответа двккл на лечение с использованием ингибитора втк - Google Patents
Биомаркеры для прогнозирования ответа двккл на лечение с использованием ингибитора втк Download PDFInfo
- Publication number
- RU2017106794A RU2017106794A RU2017106794A RU2017106794A RU2017106794A RU 2017106794 A RU2017106794 A RU 2017106794A RU 2017106794 A RU2017106794 A RU 2017106794A RU 2017106794 A RU2017106794 A RU 2017106794A RU 2017106794 A RU2017106794 A RU 2017106794A
- Authority
- RU
- Russia
- Prior art keywords
- bccc
- modification
- use according
- paragraphs
- amino acid
- Prior art date
Links
- 239000000090 biomarker Substances 0.000 title claims 4
- 239000003112 inhibitor Substances 0.000 title 1
- 230000004048 modification Effects 0.000 claims 15
- 238000012986 modification Methods 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 5
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 claims 5
- 101000984620 Homo sapiens Low-density lipoprotein receptor-related protein 1B Proteins 0.000 claims 5
- 101000742859 Homo sapiens Retinoblastoma-associated protein Proteins 0.000 claims 5
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 claims 5
- 101000795659 Homo sapiens Tuberin Proteins 0.000 claims 5
- 102100031955 Lon protease homolog, mitochondrial Human genes 0.000 claims 5
- 102100027121 Low-density lipoprotein receptor-related protein 1B Human genes 0.000 claims 5
- 102100038042 Retinoblastoma-associated protein Human genes 0.000 claims 5
- 102100031638 Tuberin Human genes 0.000 claims 5
- 102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 claims 4
- 102100027768 Histone-lysine N-methyltransferase 2D Human genes 0.000 claims 4
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 4
- 101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 claims 4
- 101000882390 Homo sapiens Histone acetyltransferase p300 Proteins 0.000 claims 4
- 101001045848 Homo sapiens Histone-lysine N-methyltransferase 2B Proteins 0.000 claims 4
- 101001008894 Homo sapiens Histone-lysine N-methyltransferase 2D Proteins 0.000 claims 4
- 101000601724 Homo sapiens Paired box protein Pax-5 Proteins 0.000 claims 4
- 101150053046 MYD88 gene Proteins 0.000 claims 4
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 claims 4
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 claims 4
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 claims 4
- 102100037504 Paired box protein Pax-5 Human genes 0.000 claims 4
- 108010038036 Receptor Activator of Nuclear Factor-kappa B Proteins 0.000 claims 4
- 102100028787 Tumor necrosis factor receptor superfamily member 11A Human genes 0.000 claims 4
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 claims 3
- 102100038885 Histone acetyltransferase p300 Human genes 0.000 claims 3
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 claims 3
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 claims 3
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 3
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 claims 3
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 3
- 229960001507 ibrutinib Drugs 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 201000006845 reticulosarcoma Diseases 0.000 claims 3
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 102220357477 c.44C>G Human genes 0.000 claims 2
- 210000001280 germinal center Anatomy 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- 108091012583 BCL2 Proteins 0.000 claims 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 claims 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 102220225706 rs1014627144 Human genes 0.000 claims 1
- 102200026940 rs148685531 Human genes 0.000 claims 1
- 102200088456 rs17220206 Human genes 0.000 claims 1
- 102220280387 rs201054129 Human genes 0.000 claims 1
- 102220005330 rs34956202 Human genes 0.000 claims 1
- 102220028791 rs398123246 Human genes 0.000 claims 1
- 102200111144 rs61751411 Human genes 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462032430P | 2014-08-01 | 2014-08-01 | |
| US62/032,430 | 2014-08-01 | ||
| US201562119668P | 2015-02-23 | 2015-02-23 | |
| US62/119,668 | 2015-02-23 | ||
| US201562127484P | 2015-03-03 | 2015-03-03 | |
| US62/127,484 | 2015-03-03 | ||
| PCT/US2015/043300 WO2016019341A1 (en) | 2014-08-01 | 2015-07-31 | Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017106794A true RU2017106794A (ru) | 2018-09-03 |
| RU2017106794A3 RU2017106794A3 (enExample) | 2019-02-27 |
Family
ID=55179406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017106794A RU2017106794A (ru) | 2014-08-01 | 2015-07-31 | Биомаркеры для прогнозирования ответа двккл на лечение с использованием ингибитора втк |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20160032404A1 (enExample) |
| EP (1) | EP3185870A4 (enExample) |
| JP (1) | JP2017523188A (enExample) |
| KR (1) | KR20170042614A (enExample) |
| CN (1) | CN106714804A (enExample) |
| AU (1) | AU2015296010A1 (enExample) |
| BR (1) | BR112017001677A2 (enExample) |
| CA (1) | CA2955744A1 (enExample) |
| IL (1) | IL250221A0 (enExample) |
| MX (1) | MX2017001302A (enExample) |
| RU (1) | RU2017106794A (enExample) |
| SG (1) | SG11201700774UA (enExample) |
| WO (1) | WO2016019341A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2350075T1 (sl) | 2008-09-22 | 2014-06-30 | Array Biopharma, Inc. | Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji |
| SG10201914059WA (en) | 2008-10-22 | 2020-03-30 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| EP2918588B1 (en) | 2010-05-20 | 2017-05-03 | Array Biopharma, Inc. | Macrocyclic compounds as TRK kinase inhibitors |
| NZ604040A (en) | 2010-06-03 | 2015-02-27 | Pharmacyclics Inc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| KR20150032340A (ko) | 2012-07-24 | 2015-03-25 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이 |
| WO2016071770A2 (en) * | 2014-11-05 | 2016-05-12 | Janssen Pharmaceutica Nv | Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same |
| US10799505B2 (en) | 2014-11-16 | 2020-10-13 | Array Biopharma, Inc. | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| MA54411B1 (fr) | 2015-04-06 | 2023-11-30 | Janssen Pharmaceutica Nv | Compositions contenant de l'ibrutinib |
| JP2018534296A (ja) | 2015-10-26 | 2018-11-22 | ロクソ オンコロジー， インコーポレイテッドＬｏｘｏ Ｏｎｃｏｌｏｇｙ， Ｉｎｃ． | Ｔｒｋ阻害薬耐性がんにおける点変異およびそれに関連する方法 |
| MX386416B (es) | 2016-04-04 | 2025-03-18 | Loxo Oncology Inc | Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida. |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| HUE063877T2 (hu) | 2016-05-18 | 2024-02-28 | Loxo Oncology Inc | (S)-N-(5-((R)-2-(2,5-dlfluorofenil)pirolidin-1-il)plrazolo[1,5-A]pirimidin-3-il) -3-hidroxipirolidin-1-karboxamid elõállítása |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| JP7356351B2 (ja) * | 2016-12-12 | 2023-10-04 | エクセラ・バイオサイエンシーズ・インコーポレイテッド | マイクロキャピラリーアレイを使用したスクリーニングのための方法およびシステム |
| US11085039B2 (en) | 2016-12-12 | 2021-08-10 | xCella Biosciences, Inc. | Methods and systems for screening using microcapillary arrays |
| WO2018125832A1 (en) | 2016-12-30 | 2018-07-05 | xCella Biosciences, Inc. | Multi-stage sample recovery system |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| EP3612192A4 (en) * | 2017-06-08 | 2020-05-27 | Enlivex Therapeutics Ltd. | THERAPEUTIC APOPTOTIC CELLS FOR CANCER THERAPY |
| CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
| CN112292117B (zh) * | 2018-06-15 | 2024-06-07 | 詹森药业有限公司 | 包含依鲁替尼的配制品/组合物 |
| GB2577909B (en) * | 2018-10-10 | 2020-11-18 | Symetrica Ltd | Gamma-ray spectrum classification |
| MX2021006368A (es) * | 2018-11-30 | 2021-10-13 | Janssen Biotech Inc | Métodos para tratar el linfoma folicular. |
| ES3039910T3 (en) | 2018-12-06 | 2025-10-27 | Xcella Biosciences Inc | Lateral loading of microcapillary arrays |
| WO2021087044A1 (en) * | 2019-10-30 | 2021-05-06 | Celgene Corporation | Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma |
| CA3209784A1 (en) * | 2021-02-03 | 2022-08-11 | Curis Inc. | Biomarkers for fimepinostat therapy |
| WO2023275330A1 (en) * | 2021-06-30 | 2023-01-05 | Janssen Pharmaceutica Nv | Treatments for diffuse large b-cell lymphoma |
| MX2023015147A (es) * | 2021-06-30 | 2024-04-01 | Janssen Pharmaceutica Nv | Inhibidores de la tirosina quinasa de bruton y métodos de su uso. |
| JP7423090B2 (ja) * | 2022-04-07 | 2024-01-29 | 学校法人藤田学園 | 不明熱患者のｂ細胞リンパ腫診断補助キットおよび情報提供方法 |
| WO2025080543A1 (en) * | 2023-10-09 | 2025-04-17 | Bristol-Myers Squibb Company | Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma |
| JP7696987B1 (ja) * | 2023-12-22 | 2025-06-23 | 東洋鋼鈑株式会社 | 遺伝子変異を検出する方法 |
| JP7698850B1 (ja) * | 2023-12-22 | 2025-06-26 | 東洋鋼鈑株式会社 | 遺伝子変異評価用キット |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ604040A (en) * | 2010-06-03 | 2015-02-27 | Pharmacyclics Inc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| CA2841142C (en) * | 2010-06-23 | 2020-12-15 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| EP2771010A4 (en) * | 2011-10-19 | 2015-04-01 | Pharmacyclics Inc | USE OF BRUTON TYROSINE KINASE (BTK) INHIBITORS |
| EP2770830A4 (en) * | 2011-10-28 | 2015-05-27 | Celgene Avilomics Res Inc | METHODS OF TREATING A DISEASE OR DISEASE ASSOCIATED WITH TYROSINE KINASE BTK (BRUTON'S TYROSINE KINASE) |
| EA201492082A1 (ru) * | 2012-06-04 | 2015-03-31 | Фармасайкликс, Инк. | Кристаллические формы ингибитора тирозинкиназы брутона |
| KR20150032340A (ko) * | 2012-07-24 | 2015-03-25 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이 |
| AU2014205577A1 (en) * | 2013-01-10 | 2015-05-28 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
-
2015
- 2015-07-31 AU AU2015296010A patent/AU2015296010A1/en not_active Abandoned
- 2015-07-31 CN CN201580049596.7A patent/CN106714804A/zh active Pending
- 2015-07-31 BR BR112017001677-0A patent/BR112017001677A2/pt not_active Application Discontinuation
- 2015-07-31 CA CA2955744A patent/CA2955744A1/en not_active Abandoned
- 2015-07-31 EP EP15828160.0A patent/EP3185870A4/en not_active Withdrawn
- 2015-07-31 JP JP2017504752A patent/JP2017523188A/ja active Pending
- 2015-07-31 MX MX2017001302A patent/MX2017001302A/es unknown
- 2015-07-31 RU RU2017106794A patent/RU2017106794A/ru not_active Application Discontinuation
- 2015-07-31 SG SG11201700774UA patent/SG11201700774UA/en unknown
- 2015-07-31 KR KR1020177005365A patent/KR20170042614A/ko not_active Withdrawn
- 2015-07-31 WO PCT/US2015/043300 patent/WO2016019341A1/en not_active Ceased
- 2015-07-31 US US14/815,921 patent/US20160032404A1/en not_active Abandoned
-
2017
- 2017-01-22 IL IL250221A patent/IL250221A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20160032404A1 (en) | 2016-02-04 |
| RU2017106794A3 (enExample) | 2019-02-27 |
| IL250221A0 (en) | 2017-03-30 |
| WO2016019341A1 (en) | 2016-02-04 |
| EP3185870A4 (en) | 2018-06-20 |
| MX2017001302A (es) | 2017-10-11 |
| JP2017523188A (ja) | 2017-08-17 |
| CA2955744A1 (en) | 2016-02-04 |
| CN106714804A (zh) | 2017-05-24 |
| BR112017001677A2 (pt) | 2018-07-17 |
| AU2015296010A1 (en) | 2017-02-02 |
| SG11201700774UA (en) | 2017-02-27 |
| KR20170042614A (ko) | 2017-04-19 |
| EP3185870A1 (en) | 2017-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017106794A (ru) | Биомаркеры для прогнозирования ответа двккл на лечение с использованием ингибитора втк | |
| JP2017523188A5 (enExample) | ||
| GB2613715B (en) | Binding proteins specific for RAS neoantigens and uses thereof | |
| EA201992063A1 (ru) | СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1 | |
| CL2017001921A1 (es) | Proteinas de union a icos | |
| SG11202106217TA (en) | Adeno-associated virus (aav) producer cell line and related methods | |
| EA201201036A1 (ru) | Целевые геномные изменения | |
| PH12015502039B1 (en) | Anti-lag-3 binding proteins | |
| MX356107B (es) | Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias. | |
| WO2016065349A3 (en) | Short non-coding protein regulatory rnas (sprrnas) and methods of use | |
| EA201190262A1 (ru) | Захватное устройство для звездообразного конвейера и звездообразный конвейер | |
| PH12015502849B1 (en) | Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers | |
| AU2016304856A8 (en) | Mechanism of resistance to BET bromodomain inhibitors | |
| DE112020000392A5 (de) | Greifvorrichtung zum Greifen von Laborgefäßen | |
| EP3867405A4 (en) | Epigenetic biomarker and uses therefor | |
| IL289749A (en) | Assay apparatuses, methods and reagents | |
| Mustonen et al. | Oligonucleotide-based pharmaceuticals: Non-clinical and clinical safety signals and non-clinical testing strategies | |
| PL3601581T3 (pl) | Sposoby hodowli komórkowej z użyciem inhibitorów hdac lub białek rep | |
| EP3494232A4 (en) | BIOMARKERS FOR PREDICTING PREMATURE DELIVERY IN A GRAVID FEMALE EXPOSED TO PROGESTOGENS | |
| EP3987267C0 (en) | TISSUE SAMPLE DISSECTION APPARATUS | |
| PH12016500371B1 (en) | Stable polypeptides binding to human complement c5 | |
| EP3992123A4 (en) | SAMPLING DEVICE | |
| EA201291345A1 (ru) | Цитруллинированные гистоновые пептиды и их применение | |
| GB201008720D0 (en) | RxLR-leader peptides and protein translocation | |
| EP3974528A4 (en) | OLIGONUCLEOTIDE, METHOD AND OMICS ANALYSIS KIT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190711 |